2024 年度募集资金存放与使用情况的专项核查意见 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关 规定，中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为广东凯普生物 科技股份有限公司（以下简称"凯普生物"或"公司"）的持续督导保荐人，对公司2024 年度募集资金存放与使用情况进行了核查。具体情况如下： 中信证券股份有限公司 关于广东凯普生物科技股份有限公司 一、募集资金基本情况 注：公司本次募集资金净额为人民币102,741.96万元，与募集资金专户实际到账金额 102,880.00万元的差额系部分发行费用尚未扣除所致。 （二）募集资金的使用及结余情况 2024年，公司单年度向特定对象发行股票募集资金合计已使用3,970.55万元。截至 2024年12月31日，公司向特定对象发行股票募集资金累计已使用74,503.56万元，部分 募投项目节余募集资金永久补充流动资金4,064.63万元，尚未使的募集资金29,445.94万 元（含理财收益及扣除手续费后的利息）。募集资金账户产生的利息收入扣除手 ...

广东凯普生物科技股份有限公司 内部控制审计报告 二○二四年度 信会师报字[2025]第 ZI10412 号 广东凯普生物科技股份有限公司 内部控制审计报告 （截止2024年12月31日） | | | 二、 事务所及注册会计师执业资质证明 内部控制审计报告 信会师报字[2025]第 ZI10412 号 广东凯普生物科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了广东凯普生物科技股份有限公司（以下简称凯普 生物）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是凯普生物董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵 ...

广东凯普生物科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为广东凯普生物科技股份有限公司（以下简称"公司"）第五届董事 会独立董事，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等相关法律法规以及《公司章程》和公司《独立董事工作 制度》等规章制度的规定和要求，在 2024 年度的任职期间，充分发挥了独立董 事及专门委员会委员的作用，恪尽职守，勤勉尽责；一方面，本人认真审核公司 提交董事会的相关事项，维护公司尤其是中小股东的利益，促进公司规范运作； 另一方面，本人发挥专业优势，积极关注和参与研究公司的发展。现将 2024 年 本人任职期间履行独立董事职责的情况汇报如下： （一）出席董事会及股东大会会议情况 2024 年度，公司共召开 12 次董事会和 2 次股东大会。本人现场参加了公司 2024 年度召开的全部董事会和股东大会，并在董事会会议上全部投了赞成票， 未出现委托出席、缺席或连续两次未亲自出席董事会的情形。 （二）出席董事会专门委员会及独立董事专门会议工作情况 一、独立董事基本情况 （一）个人工作履历及专业背景 陈英实，中央广播电视大学 ...

杨春学，获云南大学经济学硕士学位、中国社会科学院研究生院经济学博士 学位；兼任中国企业财务管理协会监事长。1986 年至 1992 年，历任云南财经大 学助教、讲师；1992 年至 1995 年，于中国社会科学院研究生院攻读博士研究生； 1995 年至 2017 年，曾任中国社会科学院经济研究所副研究员、研究员、副所长、 纪委书记、《经济学动态》主编、经济系主任；2017 年至今担任首都经济贸易大 学经济学院教授、校学术委员会主任；现任公司独立董事，并担任公司第五届董 事会战略委员会委员、薪酬与考核委员会主任委员和审计委员会委员。 广东凯普生物科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为广东凯普生物科技股份有限公司（以下简称"公司"）第五届董事 会独立董事，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等相关法律法规以及《公司章程》和公司《独立董事工作 制度》等规章制度的规定和要求，在 2024 年度的任职期间，充分发挥了独立董 事及专门委员会委员的作用，恪尽职守，勤勉尽责；一方面，本人认真审核公司 提交董事会的相关事项，维护公司尤其是中 ...

广东凯普生物科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为广东凯普生物科技股份有限公司（以下简称"公司"）第五届董事 会独立董事，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司独立董事管理办法》等相关法律法规以及《公司章程》和公司《独立董事工作 制度》等规章制度的规定和要求，在 2024 年度的任职期间，充分发挥了独立董 事及专门委员会委员的作用，恪尽职守，勤勉尽责；一方面，本人认真审核公司 提交董事会的相关事项，维护公司尤其是中小股东的利益，促进公司规范运作； 另一方面，本人发挥专业优势，积极关注和参与研究公司的发展。现将 2024 年 本人任职期间履行独立董事职责的情况汇报如下： 一、独立董事基本情况 2024 年度，本人作为公司独立董事、董事会战略委员会委员、董事会薪酬与 考核委员会委员和董事会提名委员会主任委员，严格按照公司《独立董事工作制 度》《董事会战略委员会工作条例》《董事会薪酬与考核委员会工作条例》《董事 会提名委员会工作条例》的有关规定认真履行职责，共参加了 7 次独立董事专门 会议、3 次薪酬与考核委员会会议和 6 次战略委员会会议，均未 ...

广东凯普生物科技股份有限公司董事会 关于独立董事独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等要求，广东凯普生物科技股份有限公司（以下简称"公司"）董事会， 就公司现任独立董事陈英实、杨春学、乔友林的独立性情况进行评估并出具如下 专项意见： 经核查独立董事陈英实、杨春学、乔友林的任职经历以及签署的相关自查文 件等，上述人员未在公司担任除独立董事和董事会专门委员会委员以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》中对独立董事独立性的相关要求。 广东凯普生物科技股份有限公司董事会 2025 年 4 月 27 日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥134,063,936.62, a decrease of 26.78% compared to ¥183,101,224.63 in the same period last year[4] - The net profit attributable to shareholders was -¥27,303,972.82, representing a decline of 90.21% from -¥14,354,781.93 year-on-year[4] - The net profit after deducting non-recurring gains and losses was a loss of RMB 24.76 million, a decrease of 55.15% year-on-year[11] - The company’s basic and diluted earnings per share were both -¥0.04, reflecting a 100.00% decrease from -¥0.02 in the same period last year[4] - Net profit for the period was a loss of ¥44,364,773.76, compared to a loss of ¥27,794,576.83 in the previous period, indicating a worsening of approximately 59.6%[25] - Operating profit was reported at a loss of ¥41,203,376.46, compared to a loss of ¥31,579,832.63 in the previous period[25] - Other comprehensive income after tax was a loss of ¥3,341,950.91, compared to a gain of ¥838,659.45 in the previous period[26] Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥46,917,997.50, a 173.25% increase from -¥64,051,381.67 in the previous year[4] - Cash flow from operating activities generated a net inflow of ¥46,917,997.50, a significant improvement compared to a net outflow of ¥64,051,381.67 in the previous period[27] - Cash flow from investing activities resulted in a net outflow of ¥15,014,670.63, compared to a net outflow of ¥28,097,475.91 in the previous period[28] - Cash and cash equivalents at the end of the period increased to ¥687,161,663.31 from ¥640,241,504.60, reflecting a growth of approximately 7.9%[28] - Total assets at the end of the reporting period were ¥4,534,458,359.26, down 1.91% from ¥4,622,985,300.71 at the end of the previous year[4] - The company has a total of 2,164,935,866.80 in current assets, a decrease from 2,225,642,938.29 at the beginning of the period[20] Cost Management - Research and development expenses were reduced by 31.00% to ¥16,764,468.20 from ¥24,295,791.99 in the previous year[7] - Sales expenses decreased by 35.69% to ¥34,586,046.30 compared to ¥53,777,285.75 in the same period last year[7] - The company plans to continue cost reduction and efficiency improvement efforts, focusing on expanding the market for molecular diagnostic products[11] Share Repurchase and Equity - The company will use its own funds and bank special repurchase loan funds to repurchase shares, with a total repurchase amount not less than RMB 50 million and not exceeding RMB 100 million[12] - The repurchase price will not exceed RMB 9.00 per share, with at least 30% of the funds coming from the company's own resources[13] - The company completed the share repurchase plan, acquiring a total of 8,453,825 shares, representing 1.31% of the total share capital, with a total expenditure of RMB 50,019,796.51[15] - The company reported a decrease in total equity from RMB 4,046,548,148.04 to RMB 3,939,623,474.83, primarily due to the repurchase of shares[23] Business Strategy and Development - The company is focusing on three main business segments: molecular diagnostic products, medical testing services, and healthcare services[10] - The company is implementing the "Kepu Kang and Medical Testing 5.0 Project" to enhance operational quality and efficiency[11] - The company has initiated the "Nucleic Acid 99 Strategy" to enhance R&D capabilities in maternal and child health and birth defect areas[17] - The company is enhancing its internal governance and product innovation to meet the demands in cervical cancer screening and maternal and child health management[10] - The company’s medical testing laboratory business is currently operating at a loss, with costs not covered by revenue[11] Investments and Certifications - The company has obtained a total of 95 medical device registration certificates, including 35 Class III medical device certificates, and 198 patent authorizations, with 115 being domestic and international invention patents[18] - The company’s long-term investments increased from RMB 36,006,411.98 to RMB 38,318,956.86, indicating growth in strategic investments[20] - The company has signed agreements with banks to extend the loan term for share repurchase funding from one year to three years[14]

Financial Performance - The company reported an operating revenue of 815.53 million yuan, a year-on-year decrease of 26.16%[5]. - The net profit attributable to shareholders was -654.88 million yuan, a year-on-year decline of 566.20%[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -659.73 million yuan, a year-on-year decrease of 682.84%[5]. - The company's operating revenue for 2024 was ¥815,528,791.93, a decrease of 26.16% compared to ¥1,104,453,848.02 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥654,881,994.73, representing a decline of 566.20% from ¥140,472,219.75 in 2023[23]. - The cash flow from operating activities for 2024 was ¥78,778,451.51, down 75.35% from ¥319,597,651.07 in 2023[23]. - The basic earnings per share for 2024 was -¥1.02, a decrease of 508.00% compared to ¥0.25 in 2023[23]. - The total assets at the end of 2024 were ¥4,622,985,300.71, a reduction of 19.26% from ¥5,725,791,018.32 at the end of 2023[23]. - The company experienced its first annual loss since listing, primarily due to price reductions in molecular diagnostic products and increased operational costs[47]. - The company recorded credit impairment losses of 608.01 million yuan and asset impairment losses of 37.75 million yuan during the reporting period[48]. Business Strategy and Focus - The company plans not to distribute cash dividends, issue bonus shares, or convert reserves into share capital[9]. - Despite the loss, the company's core business and competitive strengths remain stable, with no significant risks to its ongoing operations[6]. - The company will continue to focus on its main business and core competencies while addressing the reasons for the loss and implementing countermeasures[6]. - Future plans and potential risks are discussed in the management's analysis section, emphasizing the need for investors to be aware of these risks[8]. - The company aims to enhance production capacity through the introduction of advanced automated equipment and digital transformation initiatives[104]. - The company is committed to digital transformation and the development of new detection methods and technologies, leveraging AI and big data[167]. - The company is focusing on major health issues such as early cancer screening and women's and children's health, aiming to provide personalized health management solutions[98]. - The company is exploring strategic partnerships and potential acquisitions to enhance its capabilities in molecular diagnostics and expand its market reach[52]. Market and Industry Insights - The company operates in the biopharmaceutical sector, which is strongly supported by national policies, and there are currently no signs of overcapacity or continuous decline in the industry[6]. - The IVD industry is experiencing unprecedented growth opportunities due to supportive policies and increasing health awareness among residents[33]. - The third-party medical laboratory (ICL) market in China is projected to grow from ¥223 billion in 2021 to ¥513 billion by 2026, with a compound annual growth rate of 18.2%[35]. - The overall market for molecular diagnostics is expected to grow at a CAGR of 10% over the next five years, providing a favorable environment for the company's growth initiatives[52]. - The molecular diagnostics industry is expected to expand due to economic development, technological maturity, and increased disposable income, but competition is intensifying with more domestic and international players entering the market[183]. Product Development and Innovation - The company is focusing on molecular diagnostics, which is a rapidly developing field with high technical requirements and significant market demand[34]. - The company has developed a comprehensive range of HPV testing products, including the HPV21 typing test kit, which is the first in China to obtain a new drug certificate, and has been used by over 75 million people[42]. - The company has developed a multi-level product matrix for infectious disease testing, including products for hepatitis B and other sexually transmitted diseases[43]. - The company is actively developing new technologies for genetic testing, including tests for hereditary diseases and drug response, which are expected to drive future growth[52]. - The company has launched a series of innovative service projects through the "Kaitong" WeChat mini-program, including assessments for various health risks such as Alzheimer's disease and cervical cancer[72]. - The company has developed a new automatic nucleic acid detection analysis system that integrates nucleic acid extraction and fluorescence PCR amplification[74]. - The company has developed a high-sensitivity hepatitis B virus nucleic acid detection kit, enhancing its infectious disease testing product line[123]. - The company is developing a vaginal gel to effectively block HPV infection and treat early histological lesions, currently in Phase II clinical trials and has obtained new drug certification from the National Medical Products Administration[120]. Regulatory and Compliance - The company has obtained a total of 92 medical device registration certificates, including 35 Class III medical device certificates[50]. - The company has achieved medical device registration for a non-invasive urine DNA methylation test kit for bladder cancer, enhancing its tumor gene testing product line[120]. - The company is committed to maintaining compliance with regulatory requirements for its diagnostic products, ensuring continued market access[126]. - The company has received multiple registrations for its automated nucleic acid extraction and purification instruments, with registration numbers including 20220014 and 20230035, indicating a focus on clinical sample processing[132]. Financial Management and Cash Flow - Total operating cash inflow decreased by 48.35% to approximately CNY 1.08 billion, primarily due to a reduction in accounts receivable recovery[140]. - Total operating cash outflow decreased by 43.45% to approximately CNY 997 million, mainly due to lower material purchases, employee wages, and tax payments[140]. - Net cash flow from operating activities dropped by 75.35% to approximately CNY 78.78 million, significantly impacted by non-cash items such as credit impairment losses[140]. - The company is focusing on accounts receivable management and its impact on financial performance[191]. - The company is prioritizing the recovery of accounts receivable, employing a dedicated management team to enhance collection efforts through various strategies[188]. Human Resources and Organizational Changes - The company has reduced its workforce by over 17% during the reporting period, reallocating human resources towards the healthcare sector while optimizing business processes[90]. - The total number of R&D personnel decreased by 53.18% from 628 in 2023 to 294 in 2024[123]. - The company introduced 35 mid-to-senior level professionals with master's degrees or higher to enhance talent quality and structure[91]. Investor Relations and Governance - The company engaged in investor relations activities with various institutions, discussing the 2023 annual report and future development plans[190]. - The company held multiple teleconferences to address investor inquiries regarding performance and strategic direction[190]. - The company has established a value management system to enhance investment value and investor returns, approved by the board on December 10, 2024[193]. - A total of 12 board meetings were conducted, with all decisions made in accordance with regulations and in the interest of shareholders[198].

证券代码：300639 证券简称：凯普生物 公告编号：2025-014 广东凯普生物科技股份有限公司 关于持股 5%以上的股东部分股份质押展期的公告 本公司及董事会全体成员保证本公告内容真实、准确和完整，没有任何虚假 记载、误导性陈述或者重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）近日接到持股 5%以上 的股东云南众合之企业管理有限公司（以下简称"云南众合之"）的函告，获悉 其将质押给红塔证券股份有限公司（以下简称"红塔证券"）的 693 万股股份办 理了质押展期手续，质押展期情况如下： 注：1.上表计算相关比例时，总股本已扣除公司回购股份数量，下同。 二、股东股份累计被质押基本情况 云南众合之部分股份质押展期后，其持有公司股份累计被质押的情况如下： | | | 占公 | | 占其 | 占公 | | 已质押股份情况 | | 未质押股份情况 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本期展期 | 所持 | | | | | | | | | 司总 | | | 司总 | 已质押 | | 未质押 | | ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-013 广东凯普生物科技股份有限公司 关于公司控股子公司取得高新技术企业证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东凯普生物科技股份有限公司（以下简称"公司"）控股子公司上 海凯普医学检验所有限公司（以下简称"上海凯普检验所"）、北京凯普医学检 验实验室有限公司（以下简称"北京凯普检验实验室"）收到《高新技术企业证 书》，具体情况如下： | 序号 | 企业名称 | 证书编号 | 发证日期 | 批准机关 | | --- | --- | --- | --- | --- | | 1 | 上海凯普检验所 | GR202431001960 | 2024-12-04 | 上海市科学技术委员会、上海 市财政局、国家税务总局上海 | | | | | | 市税务局 | | 2 | 北京凯普检验实验室 | GR202411008246 | 2024-12-31 | 北京市科学技术委员会、北京 市财政局、国家税务总局北京 | | | | | | 市税务局 | 上海凯普检验所获得《高新技术企业证 ...